Biosynex H1 2026 net loss narrows 92% to EUR 4.2 million

• Biosynex’s first-half 2026 net loss attributable to shareholders narrowed 91% to EUR 4.2 million from a year earlier.
• Revenue fell 10% to EUR 45.3 million.
• Third-quarter 2026 revenue held steady year over year at EUR 21 million.
• The group exited safeguard proceedings following court approval of its restructuring plan on October 12, 2026.
• Auditors expect to retain a qualification over intangible asset valuations, citing insufficient evidence supporting business-plan assumptions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosynex SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2419866_fr) on October 21, 2026, and is solely responsible for the information contained therein.